Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Subscribe To Our Newsletter & Stay Updated
